Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / N••••••• P••••••• L••

Isto B•••••••• strengthens its bone graft substitutes platform with the acquisition of N•••••••

Add-on acquisitionannouncedadd-onannounced Aug 4, 2026Fact
What happened
Target
N••••••• P••••••• L••
Platform
I••• B•••••••• •add-on basis: Isto B•••••••• (“Isto”), a biologics company dedicated to advancing bone healing, today announced the acquisition of N••••••• P••••••• L•• (“N•••••••”), a developer and manufacturer of synthetic bone graft products, from H•••• p••. | Isto B•••••••• is held by K•••••••• C•••••• on its portfolio page; published on K•••••••• C••••••'s own news page
Control
Control
Share acquired
unknown
Industry
unknown
Target location
FL, US
Seller kind
Corporate parent
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
5 named
Buy side
  • I••• B•••••••• •Platformconfirmed
    “Isto B•••••••• (“Isto”), a biologics company dedicated to advancing bone healing, today announced the acquisition of N••••••• P••••••• L•• (“N•••••••”), a developer and manufacturer of synthetic bone graft products, from H•••• p••. | Isto B•••••••• is held by K•••••••• C•••••• on its portfolio page;”
  • K•••••••• C••••••Sponsorconfirmed
    “Isto B•••••••• (“Isto”), a biologics company dedicated to advancing bone healing, today announced the acquisition of N••••••• P••••••• L•• (“N•••••••”), a developer and manufacturer of synthetic bone graft products, from H•••• p••. | Isto B•••••••• is held by K•••••••• C•••••• on its portfolio page;”
Sell side
  • H•••• p••Sellerconfirmed
    “Isto B•••••••• (“Isto”), a biologics company dedicated to advancing bone healing, today announced the acquisition of N••••••• P••••••• L•• (“N•••••••”), a developer and manufacturer of synthetic bone graft products, from H•••• p••.”
Side not stated
  • N••• T•••••Managementconfirmed
    “Brian Barnes, CEO, and N••• T•••••, President of Isto B••••••••, said: “ This acquisition is a transformative milestone for Isto.”
  • N••••••• P••••••• L••Targetconfirmed
    “Isto B•••••••• (“Isto”), a biologics company dedicated to advancing bone healing, today announced the acquisition of N••••••• P••••••• L•• (“N•••••••”), a developer and manufacturer of synthetic bone graft products, from H•••• p••.”
Evidence
“Isto B•••••••• (“Isto”), a biologics company dedicated to advancing bone healing, today announced the acquisition of N••••••• P••••••• L•• (“N•••••••”), a developer and manufacturer of synthetic bone graft products, from H•••• p••.”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 15, 2026
Isto B•••••••• strengthens its bone graft substitutes platform with the acquisition of N•• | Private Equity Intelligence | DFX